论文部分内容阅读
目的:分析参麦注射液导致过敏性休克的特点,为临床合理用药提供参考。方法:以“参麦注射液”为关键词,检索全国期刊全文数据库(CNKI)、中文科技期刊数据库(VIP)、万方数据库。汇总所搜集病例的惠者情况、用药情况及过敏性休克发生情况。结果:共收集个案报道28例。男12例,女16例,年龄最小12岁,最大78岁。不符合适应证用药16例。用药剂量均在说明书规定范围内,首次用药发病25例,再次用药发病3例。首次用药病例中,一次用量为50～100 ml的15例,20～40 ml 10例。过敏性休克发生于用药中的26例,均在用药20 min内发病。用药后20 min发病的患者有1例。28例患者经治疗均恢复正常,无后遗症。结论:参麦注射剂导致过敏性休克发病迅速,及时救治,转归好。临床用药应对重点患者加强监护,严格遵守适应证,控制首次用药剂量,加强用药中、用药后监护。
Objective: To analyze the characteristics of Shenmai injection in causing anaphylactic shock and provide reference for clinical rational drug use. Methods: Using “Shenmai Injection” as the key word, CNKI, VIP, Wanfang database were searched. Summarizes the beneficiaries of the cases collected, medication and the occurrence of anaphylactic shock. Results: A total of 28 cases were collected. There were 12 males and 16 females, the youngest was 12 years old and the oldest was 78 years old. 16 cases did not meet the indications medication. Medication dosage are within the scope of the instructions, the first time the incidence of medication in 25 cases, again medication in 3 cases. For the first time, 15 cases of 50-100 ml and 10 cases of 20-40 ml were used in one dose. Anaphylactic shock occurred in the treatment of 26 cases, were treated within 20 min onset. One patient developed disease 20 min after treatment. 28 patients returned to normal after treatment, no sequelae. Conclusion: Shenmai injection led to the rapid onset of anaphylactic shock, timely treatment, go well. Clinical medication should strengthen the guardianship of key patients, strictly abide by the indications, control the first dose, to strengthen the medication, medication care.